This company has been marked as potentially delisted and may not be actively trading.

Mirati Therapeutics (MRTX) Competitors

MRTX vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Mirati Therapeutics stock or one of its competitors? The main competitors of Mirati Therapeutics include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Mirati Therapeutics compare to MANE?

Mirati Therapeutics (NASDAQ:MRTX) and MANE (NYSE:MANE) are both mid-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

: MANE has a net margin of 0.00% compared to Mirati Therapeutics' net margin of -1,900.65%. MANE's return on equity of 0.00% beat Mirati Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Mirati Therapeutics -1,900.65% -82.15% -67.82%
MANE N/A N/A N/A
: In the previous week, MANE had 5 more articles in the media than Mirati Therapeutics. MarketBeat recorded 5 mentions for MANE and 0 mentions for Mirati Therapeutics. MANE's average media sentiment score of 0.68 beat Mirati Therapeutics' score of 0.00 indicating that MANE is being referred to more favorably in the news media.
Company Overall Sentiment
Mirati Therapeutics Neutral
MANE Positive
: MANE has lower revenue, but higher earnings than Mirati Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mirati Therapeutics $12.44M 331.01 -$740.87M -$12.22 N/A
MANE N/A N/A N/A N/A N/A
: MANE has a consensus target price of $83.33, indicating a potential downside of 25.04%. Given MANE's stronger consensus rating and higher possible upside, analysts plainly believe MANE is more favorable than Mirati Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirati Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80

Company	Net Margins	Return on Equity	Return on Assets
Mirati Therapeutics	-1,900.65%	-82.15%	-67.82%
MANE	N/A	N/A	N/A

Company	Overall Sentiment
Mirati Therapeutics	Neutral
MANE	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirati Therapeutics	$12.44M	331.01	-$740.87M	-$12.22	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirati Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

MANE beats Mirati Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Mirati Therapeutics compare to Kailera Therapeutics?

Mirati Therapeutics (NASDAQ:MRTX) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

: Kailera Therapeutics has a net margin of 0.00% compared to Mirati Therapeutics' net margin of -1,900.65%. Kailera Therapeutics' return on equity of 0.00% beat Mirati Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Mirati Therapeutics -1,900.65% -82.15% -67.82%
Kailera Therapeutics N/A N/A N/A
: In the previous week, Kailera Therapeutics had 1 more articles in the media than Mirati Therapeutics. MarketBeat recorded 1 mentions for Kailera Therapeutics and 0 mentions for Mirati Therapeutics. Mirati Therapeutics' average media sentiment score of 0.00 equaled Kailera Therapeutics'average media sentiment score.
Company Overall Sentiment
Mirati Therapeutics Neutral
Kailera Therapeutics Neutral
: Kailera Therapeutics has lower revenue, but higher earnings than Mirati Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mirati Therapeutics $12.44M 331.01 -$740.87M -$12.22 N/A
Kailera Therapeutics N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Mirati Therapeutics	-1,900.65%	-82.15%	-67.82%
Kailera Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
Mirati Therapeutics	Neutral
Kailera Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirati Therapeutics	$12.44M	331.01	-$740.87M	-$12.22	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Mirati Therapeutics on 4 of the 5 factors compared between the two stocks.

How does Mirati Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

: Gemini Therapeutics has higher earnings, but lower revenue than Mirati Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A
Mirati Therapeutics $12.44M 331.01 -$740.87M -$12.22 N/A
: Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
: 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 3.3% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Gemini Therapeutics has a net margin of 0.00% compared to Mirati Therapeutics' net margin of -1,900.65%. Gemini Therapeutics' return on equity of -38.78% beat Mirati Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Gemini Therapeutics N/A -38.78% -35.88%
Mirati Therapeutics -1,900.65% -82.15% -67.82%
: In the previous week, Gemini Therapeutics had 1 more articles in the media than Mirati Therapeutics. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Mirati Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 equaled Mirati Therapeutics'average media sentiment score.
Company Overall Sentiment
Gemini Therapeutics Neutral
Mirati Therapeutics Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Mirati Therapeutics	$12.44M	331.01	-$740.87M	-$12.22	N/A

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Mirati Therapeutics	-1,900.65%	-82.15%	-67.82%

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Mirati Therapeutics	Neutral

Summary

Gemini Therapeutics beats Mirati Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Mirati Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

: MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
: 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 3.3% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Mirati Therapeutics'average media sentiment score.
Company Overall Sentiment
MorphoSys Neutral
Mirati Therapeutics Neutral
: MorphoSys has a net margin of -226.79% compared to Mirati Therapeutics' net margin of -1,900.65%. Mirati Therapeutics' return on equity of -82.15% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Mirati Therapeutics -1,900.65% -82.15% -67.82%
: MorphoSys has higher revenue and earnings than Mirati Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Mirati Therapeutics $12.44M 331.01 -$740.87M -$12.22 N/A

Company	Overall Sentiment
MorphoSys	Neutral
Mirati Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Mirati Therapeutics	-1,900.65%	-82.15%	-67.82%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Mirati Therapeutics	$12.44M	331.01	-$740.87M	-$12.22	N/A

Summary

MorphoSys beats Mirati Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Mirati Therapeutics compare to Zymeworks?

Mirati Therapeutics (NASDAQ:MRTX) and Zymeworks (NASDAQ:ZYME) are both mid-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

: Mirati Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
: 92.9% of Zymeworks shares are held by institutional investors. 3.3% of Mirati Therapeutics shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: In the previous week, Zymeworks had 3 more articles in the media than Mirati Therapeutics. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Mirati Therapeutics. Zymeworks' average media sentiment score of 0.56 beat Mirati Therapeutics' score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.
Company Overall Sentiment
Mirati Therapeutics Neutral
Zymeworks Positive
: Zymeworks has a consensus target price of $37.89, suggesting a potential upside of 38.56%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Mirati Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirati Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Zymeworks
1 Sell rating(s)

1 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.92
: Zymeworks has a net margin of -76.56% compared to Mirati Therapeutics' net margin of -1,900.65%. Zymeworks' return on equity of -26.00% beat Mirati Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Mirati Therapeutics -1,900.65% -82.15% -67.82%
Zymeworks -76.56% -26.00% -20.57%
: Zymeworks has higher revenue and earnings than Mirati Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mirati Therapeutics $12.44M 331.01 -$740.87M -$12.22 N/A
Zymeworks $105.96M 19.03 -$81.13M -$1.08 N/A

Company	Overall Sentiment
Mirati Therapeutics	Neutral
Zymeworks	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirati Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Company	Net Margins	Return on Equity	Return on Assets
Mirati Therapeutics	-1,900.65%	-82.15%	-67.82%
Zymeworks	-76.56%	-26.00%	-20.57%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirati Therapeutics	$12.44M	331.01	-$740.87M	-$12.22	N/A
Zymeworks	$105.96M	19.03	-$81.13M	-$1.08	N/A

Summary

Zymeworks beats Mirati Therapeutics on 15 of the 17 factors compared between the two stocks.

Get Mirati Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRTX vs. The Competition

Export

Metric	Mirati Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.12B	$894.88M	$6.28B	$12.08B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-4.80	1.71	29.20	27.30
Price / Sales	331.01	118.37	491.35	76.15
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	3.39	7.63	9.75	6.73
Net Income	-$740.87M	-$4.80M	$3.55B	$332.77M

Mirati Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
MRTX Mirati Therapeutics	N/A	$58.70 flat	N/A	N/A	$4.12B	$12.44M	N/A	587
MANE MANE	N/A	$103.67 -2.7%	$83.33 -19.6%	N/A	$3.86B	N/A	N/A	19
KLRA Kailera Therapeutics	N/A	$25.08 +1.3%	N/A	N/A	$3.10B	N/A	N/A	145
GMTX Gemini Therapeutics	N/A	$67.26 -2.3%	N/A	+36.6%	$2.91B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRTX) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirati Therapeutics (MRTX) Competitors

MRTX vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Mirati Therapeutics compare to MANE?

Summary

How does Mirati Therapeutics compare to Kailera Therapeutics?

Summary

How does Mirati Therapeutics compare to Gemini Therapeutics?

Summary

How does Mirati Therapeutics compare to MorphoSys?

Summary

How does Mirati Therapeutics compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRTX vs. The Competition

Mirati Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirati Therapeutics (MRTX) Competitors

MRTX vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Mirati Therapeutics compare to MANE?

Summary

How does Mirati Therapeutics compare to Kailera Therapeutics?

Summary

How does Mirati Therapeutics compare to Gemini Therapeutics?

Summary

How does Mirati Therapeutics compare to MorphoSys?

Summary

How does Mirati Therapeutics compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRTX vs. The Competition

Mirati Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools